Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TEVA R&D Increase and Bristol Recruit Emphasize Biosimilars

This article was originally published in RPM Report

Executive Summary

The Obama Administration failed to clarify the biosimlar pathway for the start of 2012 with promised guidances, but the big players in biosimilars think they have a good fix on what the space will look like from a regulatory/development perspective. Take TEVA; the generic company’s actions and statements at the end of 2011 announce clearly that it sees a development-intensive, beyond-generic space developing in biosimilars.


Related Content

Believing In Biosimilars: Industry Takes Long View on FDA Pathway


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts